bioRxivCancer BiologyPreprint
The subclonal footprint of pervasive early dissemination in pancreatic cancer
Yuanchang FangiD, Michelle Chan‐Seng‐YueiD, Karen NgiD, Amy Xin Wei ZhangiD, Tuan Anh HoangiD, Gun Ho JangiD, Sabiq Chaudhary, Catia Gaspar, Eugenia Flores FigueroaiD, Daniela Bevacqua, Stephanie RamotariD, Ayelet BorgidaiD, Shawn HutchinsoniD, Anna DoddiD, Ayah Elqaderi, Maryam MonajemzadehiD, Yifan WangiD, Stanley NgiD, Spring Holter, Barbara T. GrünwaldiD, Julie M. WilsoniD, Robert C. GrantiD, Erica S. TsangiD, George ZogopoulosiD, Masoom A. HaideriD, , Faiyaz NottaiD
Abstract
Early is too late describes a central problem in pancreatic cancer referring to its relentless drive to disseminate and highlights the need to understand how this disease spreads so rapidly. In this study, we profiled 1,013 samples from 277 donors, including tissue whole genome and RNA sequencing combined with plasma whole genome sequencing at [~]25x. Strikingly, local primary tumours, including some reaching 7cm, were found to shed little to no circulating tumour DNA (ctDNA). Instead, metastatic burden in the liver but not extrahepatic sites, was a main physiologic determinant of ctDNA levels. Whole-genome duplication (WGD), high cell cycle activity, and non-glandular differentiation emerged as tumour-intrinsic features related to increased ctDNA shedding. By contrast, decreased shedding was related to extrinsic features including a reactive microenvironment and unexpectedly, humoral immunity. Analysis of tumour clonal architecture showed that in patients with low ctDNA levels, the signal disproportionately originated from subclones and this signal persisted even when the primary tumour was removed. Disseminated subclones were a significant source of ctDNA in early-stage patients. Longitudinal analysis of patients revealed that subclones seeded metastases and shed ctDNA in the blood years before detection. This first report of paired tissue and plasma whole genomes in pancreatic cancer is a unique resource and has broad implications for disease surveillance, treatment monitoring, and early detection in this disease.
- organism: human
- assay: whole-genome sequencing
- assay: whole-exome sequencing
- assay: bulk RNA-seq
- research focus: clustering
- research focus: differential expression
- research focus: cell type annotation
- research focus: gene regulatory network inference
- approach: statistical model
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Transcriptomic plasticity is a hallmark of metastatic pancreatic cancer
Alejandro Jiménez-Sánchez, Sitara Persad, … Dana Pe’er·Cancer ResearchPeer-reviewed·Dec 11, 2025
- Low abundance of circulating tumor DNA in localized prostate cancer
S. Thomas Hennigan, Shana Y. Trostel, … Adam G. Sowalsky·JCO Precision OncologyPeer-reviewed·Sep 9, 2019
- Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer
Erica D. Pratt, David Bing Zhen, … Andrew D. Rhim·bioRxiv·Mar 28, 2021
- Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer
- High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Emily R. Greene, Natalie K. Horvat, … Gregory B. Lesinski·bioRxiv·Apr 18, 2025
- Pan-cancer whole genome analyses of metastatic solid tumors
P. Priestley, J. Baber, … E. Cuppen·bioRxiv·Aug 12, 2019